journal cover

In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma

Nature Biotechnology

Sep 25, 2019

Lupeng YeSidi Chen

Abstract

Targeting membrane proteins could improve the efficacy of T cell-based immunotherapies. To facilitate the identification of T cell targets, we developed a hybrid genetic screening system where the Sleeping Beauty (SB) transposon and single guide RNA cassette are nested in an adeno-assoc...read more

Mentioned in this Paper

In Vivo
LAG3
T-Lymphocyte
Membrane
CRISPR-Cas Systems
Gene Editing
Mandibular Right Second Primary Molar
Genetic Screening (Procedure)
Nucleic Acid Sequencing
Mutant Chimeric Proteins
113
5
117
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Downstream Antiviral T Cell

Epigenome Engineering (Keystone)

Recent advances in epigenome engineering technologies allow now for the large-scale assessment of the functional relevance of DNA methylation. Discover the latest research here.

Non-Small Cell Lung Cancer Recurrence

Epigenome Engineering

Recent advances in epigenome engineering technologies allow now for the large-scale assessment of the functional relevance of dna methylation. Discover the latest research here.

Crispr In Malaria

CRISPR-Cas system enables the editing of genes to create or correct mutations. This technology is being investigated to combat malaria by targeting specific stretches of vector DNA and editing the genome at precise locations. Here is the latest research.

Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is a tumor that develops from astrocytes and oligodendrocytes. Here is the latest research on mechanisms that underlie GBM and associated therapeutic approaches.

Genome Editing & T-Cells

Genome editing technologies enable the editing of genes to create or correct mutations or express genes of interest. Here is the latest research on genome editing in T- cells and their application in human diseases such as adoptive T-cell immunotherapy for cancer.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

T cells: Costimulatory Receptors

T cell activation requires engagement of both the T cell receptor and a co-stimulatory molecule. Lack of a co-stimulatory signal can result in T cell anergy, deletion, or immune tolerance. Find the latest research on T cell co-stimulatory receptors here.

Cross-Priming

Cross-priming is the process whereby professional APC, mainly dendritic cells, prime t-cells by presenting antigens processed from proteins of other cells such as tumor cells or virus-infected cells. Discover the latest research on cross-priming here.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

© 2020 Meta ULC. All rights reserved

In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma

Nature Biotechnology

Sep 25, 2019

Lupeng YeSidi Chen

PMID: 31548728

DOI: 10.1038/s41587-019-0246-4

Abstract

Targeting membrane proteins could improve the efficacy of T cell-based immunotherapies. To facilitate the identification of T cell targets, we developed a hybrid genetic screening system where the Sleeping Beauty (SB) transposon and single guide RNA cassette are nested in an adeno-assoc...read more

Mentioned in this Paper

In Vivo
LAG3
T-Lymphocyte
Membrane
CRISPR-Cas Systems
Gene Editing
Mandibular Right Second Primary Molar
Genetic Screening (Procedure)
Nucleic Acid Sequencing
Mutant Chimeric Proteins
113
5
117

Similar Papers Found In These Feeds

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.
/papers/in-vivo-crispr-screening-in-cd8-t-cells-with-aav-s/31548728